{"organizations": [], "uuid": "9077c41a055faff65e1f34b6aa974797cacbc916", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/us", "section_title": "US Stock Market News - Dow Jones, Nasdaq, S&amp;P 500 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-says-first-time-data-for-key/brief-merck-says-first-time-data-for-keytruda-in-patients-with-previously-treated-advanced-hepatocellular-carcinoma-to-be-presented-at-2018-asco-gi-symposium-idUSFWN1PE0IN", "country": "US", "domain_rank": 408, "title": "Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 ASCO GI Symposium", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-01-19T20:16:00.000+02:00", "replies_count": 0, "uuid": "9077c41a055faff65e1f34b6aa974797cacbc916"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-says-first-time-data-for-key/brief-merck-says-first-time-data-for-keytruda-in-patients-with-previously-treated-advanced-hepatocellular-carcinoma-to-be-presented-at-2018-asco-gi-symposium-idUSFWN1PE0IN", "ord_in_thread": 0, "title": "Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 ASCO GI Symposium", "locations": [], "entities": {"persons": [], "locations": [{"name": "patien", "sentiment": "none"}], "organizations": [{"name": "asco", "sentiment": "neutral"}, {"name": "merck", "sentiment": "neutral"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - Merck & Co Inc:\n* FIRST-TIME DATA FOR MERCK‘S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM\n* MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES\n* MERCK & CO INC - SEVEN PATIENTS DISCONTINUED TREATMENT DUE TO TREATMENT-RELATED ADVERSE EVENTS\n* MERCK & CO INC - THERE WAS ONE TREATMENT-RELATED DEATH IN THE STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-19T20:16:00.000+02:00", "crawled": "2018-01-19T14:21:01.118+02:00", "highlightTitle": ""}